Real world evidence for legacy effect of early glycaemic control in type 2 diabetes on risk of macrovascular disease

Real world evidence for legacy effect of early glycaemic control in type 2 diabetes on risk of macrovascular disease

Detalles Bibliográficos
Autores principales:	Whyte, M, Hoang, U, Hinton, W, McGovern, AP, Munro, N, de Lusignan, S
Formato:	Conference item
Lenguaje:	English
Publicado:	Springer 2017

Ejemplares similares

What predicts early glycaemic control in people with type 2 diabetes?
por: McGovern, AP, et al.
Publicado: (2017)

Glycaemic trajectories in type 2 diabetes and risk of cardiovascular disease: Exploring the link
por: Whyte, MB, et al.
Publicado: (2019)

Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
por: McGovern, A, et al.
Publicado: (2016)

The association between diabetes, level of glycaemic control and eye infection: cohort database study
por: Ansari, A, et al.
Publicado: (2017)

Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: a primary care cohort study
por: Whyte, MB, et al.
Publicado: (2022)

Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis
por: Whyte, M, et al.
Publicado: (2019)

Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis.
por: Martin B Whyte, et al.
Publicado: (2019-10-01)

Ethnic and socioeconomic disparities in type 2 diabetes care: A trend analysis
por: Hinton, W, et al.
Publicado: (2017)

A class comparison of medication persistence in people with type 2 diabetes: A retrospective observational study
por: McGovern, A, et al.
Publicado: (2018)

Ethnic disparities in medication persistence in Type 2 diabetes: non-whites have reduced persistence
por: McGovern, AP, et al.
Publicado: (2016)

Disparities in the monitoring and complication screening of people with Type 2 diabetes
por: Hinton, W, et al.
Publicado: (2017)

Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta‐analysis
por: McGovern, A, et al.
Publicado: (2017)

Systematic review of adherence rates by medication class in type 2 diabetes: a study protocol
por: McGovern, A, et al.
Publicado: (2016)

Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use
por: McGovern, A, et al.
Publicado: (2017)

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol)
por: McGovern, A, et al.
Publicado: (2017)

Disparities in prescribing of sodium-glucose co-transporter-2 (SGLT2) inhibitors and DPP-4 inhibitors in people with Type 2 diabetes and chronic kidney disease (CKD)
por: Shah, S, et al.
Publicado: (2018)

Does the presence of NAFLD influence prescribing behaviour in Type 2 diabetes?
por: Whyte, MB, et al.
Publicado: (2017)

Glycemic control is an important modifiable risk factor for uveitis in patients with diabetes: A retrospective cohort study establishing clinical risk and ophthalmic disease burden
por: Ansari, AS, et al.
Publicado: (2018)

Association between glycaemic control and common infections in people with Type 2 diabetes: a cohort study
por: Hine, J, et al.
Publicado: (2016)

Association between diabetes, level of glycemic control, and eye infection: a cohort study
por: Ansari, A, et al.
Publicado: (2016)

GLP-1 RA treatment: a benefit-risk analysis from a retrospective cohort study
por: Konstantara, E, et al.
Publicado: (2018)

Does real world use of liraglutide match its use in the LEADER cardiovascular outcome trial? study protocol
por: Hinton, W, et al.
Publicado: (2019)

Differences in persistence by class of oral therapy for the treatment of type 2 diabetes
por: McGovern, AP, et al.
Publicado: (2016)

Creating and using real-world evidence to answer questions about clinical effectiveness
por: Simon de Lusignan, et al.
Publicado: (2015-11-01)

Measuring quality of healthcare outcomes in type 2 diabetes from routine data: a seven-nation survey conducted by the IMIA Primary Health Care Working Group
por: Hinton, W, et al.
Publicado: (2017)

A national audit of SGLT2 use in England
por: McGovern, A, et al.
Publicado: (2017)

Is diabetes really a risk factor for acute eye infection?
por: Ansari, AS, et al.
Publicado: (2017)

Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (type 3c): A retrospective cohort study
por: Woodmansey, C, et al.
Publicado: (2017)

Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
por: Hinton, W, et al.
Publicado: (2019)

Fenofibrate as a COVID-19 modifying drug: laboratory success versus real-world reality
por: Feher, M, et al.
Publicado: (2021)

Evidence for congruent impairment in micro and macrovascular function in type 1 diabetes.
por: Concetta Irace, et al.
Publicado: (2017-01-01)

Preconception folic acid uptake in women with diabetes of childbearing age: findings from the Royal College of General Practitioners Research Surveillance Centre
por: Coleman, M, et al.
Publicado: (2017)

Envolvimento macrovascular e esclerose sistêmica Macrovascular involvement and systemic sclerosis
por: Emmanuelle Tenório Albuquerque Madruga Godoi, et al.
Publicado: (2009-03-01)

The distinct epidemiology of 'Type 3c' diabetes should prompt consideration of chronic pancreatic disease as the possible cause of a patient's diabetes
por: Woodmansey, C, et al.
Publicado: (2017)

Type 2 Diabetes Mellitus and Macrovascular Complications
por: Peng-Fei Shan, et al.
Publicado: (2017-01-01)

What are the HbA(1c) thresholds for initiating insulin therapy in people with type 2 diabetes in UK primary care?
por: Hinton, W, et al.
Publicado: (2016)

Phenotype execution and modeling architecture to support disease surveillance and real-world evidence studies: English sentinel network evaluation
por: Jamie, G, et al.
Publicado: (2024)

Molecular Mechanisms of Methylglyoxal in Diabetes-related Macrovascular Complications
por: Anna Meiliana, et al.
Publicado: (2024-10-01)

Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?
por: Aastha Chawla, et al.
Publicado: (2016-01-01)

Macrovascular complication phenotypes in type 2 diabetic patients
por: Papa Giuseppe, et al.
Publicado: (2013-01-01)